app_store_button

google_play_button

Copy of Device Banner Block 894x1036 3

Descubre un mundo infinito de historias

Escucha y lee

Andreessen Horowitz

16 Minutes News by a16z

original episode notes and transcript here: 

https://future.a16z.com/podcasts/malaria-vaccine-tech-science-news/ 

Longtime podcast showrunner (2014-2022), primary host, and editor Sonal Chokshi shares three best-of episodes as she shifts gears and the show goes on hiatus until relaunched with a new host. 

As with all of the episodes on this show about tech & science trends in the news, and where they are on the long arc of innovation -- this one is actually a story of human ingenuity over 100 years in the making, with the ultimate breakthrough in a malaria vaccine just last year that we discuss here. (And while we were one of the very first to cover the coronavirus pandemic back in Jan 2020, and several episodes all about vaccines, this is an unusual one: fighting a parasite vs a virus, what that means, how, and why it matters.)

It is also one of Chokshi's signature “2x explainers”, where we quickly cover the headlines and tech trends, but also offer evergreen explainers, analysis, frameworks, and more to understand those trends -- whether it was TikTok’s algorithm, GPT-3, the opioid crisis, or the anatomy of a hack. 

Thank you to you all for listening, sharing, engaging and coming along with us on this journey! Thank you as well to our brilliant audio editors, expert guests, and several others. The team will be putting this feed on hiatus temporarily, and in the meantime, you can follow my other work here at a16z as well as other projects on Twitter @smc90. Stay tuned for more!

Parasite, the Malaria (Tech & Science) Edition

Welcome to 16 Minutes, our podcast where we discuss tech trends in the news and their impact on the long arc of innovation. Today’s topic is crypto regulation, and specifically, two recent federal government hearings in the news that were focused on crypto and therefore the related trend of web3. In contrast to the model of web2 — typified by very broadly used but also very centralized platforms run by corporations — web3 refers to the idea of a new internet enabled by crypto that is owned by builders and users.

The first hearing that took place was at the House Committee on Financial Services, featuring six crypto company CEOs and resulting in a five-hour session that prompted headlines like “Congress Gets a Crash Course on Cryptocurrency.” 

Then, just last week, the U.S. Senate’s Banking, Housing, and Urban Affairs Committee held its own hearing, this time focused on stablecoins, which are privately issued cryptocurrencies that are pegged to a stable asset such as the U.S. dollar, and are used in decentralized financial services. 

We’ve covered crypto regulatory issues on 16 Minutes before with a16z experts, including an episode with former federal prosecutor Katie Haun and former New York Stock Exchange regulatory chief Anthony Albanese. That discussion, which you can find in this feed under episode #50, was about a proposal by the Treasury Department’s financial crimes enforcement arm that included provisions for digital asset reporting. 

(As a reminder, none of the following should be taken as investment advice, please see a16z.com/disclosures for more important information.) 

All of these hearings are also connected to the broader question of innovation, and keeping the U.S. competitive on a global stage.

So with that context, our guest today is a16z global head of policy Tomicah Tillemann, who before joining a16z served as senior advisor to two secretaries of state. He reports on the hearings and their significance, and gives a quick pulse-check on where we are with crypto regulation right now.

Crypto at Congress: 'Watershed' Moment for Regulation and Web3

Welcome to 16 Minutes, our show on the a16z podcast network where we talk about tech trends that are dominating news headlines, industry buzz, and where we are on the long arc of innovation. 

Today’s episode actually features a look back at the GameStop saga — the stock market drama that some headlines described as a “David-and-Goliath battle” that quote “upended Wall Street.” 

For quick basic context, here’s what happened: A group of Reddit users mass-purchased and drove up prices of stock in the video game retailer GameStop, forcing short sellers including hedge funds and institutional investors to back out in a short squeeze, pushing prices even higher. But beyond the news, this also portended other, broader trends including redefining the power of retail investors, the phenomenon of meme stocks, and more. 

So in this episode — which is from a conversation that originally took place live on Clubhouse (and which, by the way, can also be found on the a16z Live feed) — a16z co-founder Marc Andreessen talks to Ken Griffin, founder and CEO of the hedge fund Citadel, which was a key player in GameStop as both a market maker and investor. You’ll also hear a16z general partner and fintech expert Alex Rampell join later in the conversation.

Griffin also just purchased (in a Sotheby’s auction a little over two weeks ago) one of the original copies of the U.S. Constitution, an auction in which a decentralized autonomous organization called ConstitutionDAO also bid on buying it. Marc and Ken touch briefly on this at the very end.

Inside the GameStop Drama; The U.S. Constitution, Auctioned

Welcome to 16 Minutes, our show where we talk about tech trends in the news. We have two segments today: 
1) The announcement recently that Valve Software, which operates the massive gaming platform Steam, added a rule against games that use blockchain technologies or that allow users to exchange cryptocurrencies or NFTs – this rule appeared on its “What you shouldn’t publish on Steam” onboarding list for developers. We go beyond the players to the trends at play here, putting the news in context — as is the premise of this show — because it not only immediately impacts gaming developers and gamers using the platform, but has implications for gaming business models and the arc of innovation in gaming as part of the web3 movement. Our expert guests are a16z partner Jonathan Lai and a16z partner Eddy Lazzarin. 
2) The FDA’s announcement last month that it authorized marketing of the “first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.” The FDA reviewed the technology from Paige Prostate through its De Novo regulatory pathway. We have three expert guests: Eli Van Allen, associate professor of Medicine at Harvard Medical School and chief of the Division of Population Sciences at the Dana-Farber Cancer Institute; a16z bio general partner Vineeta Agarwala; and a16z bio partner Jay Rughani.

Steam Halts Web3 Games; FDA Approves Prostate Cancer AI

In today’s episode we have two short segments, both on bioscience topics:

[0:00] Moderna has started clinical trials for a flu vaccine, called mRNA-1010, that is based on the same mRNA technology that Moderna and Pfizer used for their COVID vaccines, and that several other companies including Sanofi and Glaxo all are actively working on for the influenza use case. Our experts are general partners Vineeta Agarwala and Jorge Conde of the a16z bio team, who have joined us on many of our vaccine-related episodes, which you can find at a16z.com/vaccines. They discuss what comes next for the clinical trials of this mRNA-based flu vaccines, why companies aren't planning to use the faster and more-targeted mRNA technology for COVID's Delta variant, and how mRNA vaccines will change not only our approach to flu shots but to other respiratory viruses. 

[9:53] Google’s DeepMind AlphaFold, in partnership with the European Molecular Biology Laboratory, is publicly sharing its entire protein structure database -- with predicted protein structure models for ~20,000 proteins expressed by the human genome -- meaning that all its data will be freely and openly available to the scientific community. (We previously discussed DeepMind's AlphaFold protein-folding AI on this show in episode #48.) General partner Vijay Pande of the a16z bio team helps us answer the question: Why does it matter that a huge database of very accurate predicted protein structures is now freely available?

mRNA for Flu Vaccine? AI Protein-Folding Goes Open Source

Given recent news of drug company settlements, calls to action, policy moves, and more, this episode is a rerun of one of our very early explainers (episode #4 of 16 Minutes, 2019) on the opioid crisis. 

Bio experts and a16z general partners Jorge Conde and Vijay Pande discuss on 16 Minutes (our shortform show where we discuss the headlines, tease apart what's hype' what's real, and where we are on the long arc of innovation) with host Sonal Chokshi: 

 • how opioids work;
 • the questions around who's to blame;
 • and other directions for managing pain.

Where could tech come in, even with the broader social, cultural, and structural context involved here?

original episode:
https://a16z.com/2019/08/04/16mins-news-opioid-crisis-dea-database/

Opioid Crisis - How, Who, and Tech

Welcome to 16 Minutes, the a16z show where we talk about tech trends in the news, what’s hype and what’s real, and the long arc of innovation.

In today's episode we’re talking about the latest developments and trends in cybercrime – including the trends of ransomware, and, attacks on physical infrastructure.

First (0:00 - 6:07), we have the recent attack on the meat processing plant JBS, the largest meat processor in the world; just last week it had to temporarily shut down some operations in the U.S., Canada, and Australia due to an attack on its servers, with the hackers demanding payment from the company. 

These types of “ransomware" attacks are increasing – recently hackers hit the Colonial Pipeline, the largest refined oil pipeline in the U.S., and disrupted fuel distribution on the East Coast. In that attack, hackers demanded and received millions in ransom, though the Justice Department announced on Monday it had recovered much of that ransom, paid in bitcoin. Hackers have also recently hit health care organizations, school systems, and even ferry services.

In the second segment (6:08 - 12:13), we’ll briefly talk about the breach of home and enterprise wireless network management technology provider Ubiquiti. Security researcher Brian Krebs reported allegations from a whistleblower, and more recently, lawsuits have been filed. Here we’ll focus on the questions it raises for security. 

Both segments feature a16z operating partner for security (and former Box CSO) Joel de la Garza. Martin Casado, a16z general partner and co-founder of networking company Nicira, joins us for the second segment.

###

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

Ransomware Attacks on the Rise; Hackers Target IoT

Given recent buzz and ongoing debates around the Endless Frontiers Act -- which some have described as “the most important piece of legislation no one's heard of” -- this episode is a rerun of an episode from last year, recorded after said act was initially unveiled. 

The short discussion covers the broader topic and theme of funding science and innovation, and R&D in general -- not just in government agencies, but corporations, and the overall landscape there as well. Notably, the name of the Endless Frontiers act was inspired by the famous memo, “Science, the Endless Frontier”, which was a report to the then U.S.-President by Vannevar Bush, Director of the Office of Scientific Research and Development in July 1945 -- and that led to the creation of the independent government agency the National Science Foundation (NSF).

For quick context (without covering current discussions/ updates in the news right now) -- the bipartisan proposal had proposed giving NSF over $100B over 5 years in funding. It had also proposed rebranding the National Science Foundation into the National "Science and Technology" Foundation, which a16z general partner Martin Casado (who has worked the full spectrum from academia to research lab to startup to big company) discusses with Sonal Chokshi in this episode. You can also find their conversation with former Stanford president John Hennessy and Marc Andreessen on the changing relationship between academia and industry at a16z.com/researchtostartup. 

original episode: 

https://a16z.com/2020/07/09/16mins-nsf-funding-science-corporate-innovation-remote-work-new-normal-future/

Science (and Tech), the Endless Frontier

Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate "malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in preprint with The Lancet, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A "weapon" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.

So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- Rajeev Venkayya of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and what's left to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?

Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been nearly a century in the making.

Malaria Vaccine Breakthrough, Beyond the Buzz

In this week’s episode of 16 Minutes, our show where we cover tech trends in the news — and also cover themes from company developer and innovation events! — we focus on the latest coming out of Apple’s event this week. The company announced a bunch of things, ranging from new device colors and form factors to podcast services, but in this episode we asked regular guest Steven Sinofsky (an a16z board partner and former Microsoft Windows president who has appeared on past event episodes including covering CES and Apple’s M1 chip) to weigh in. He shares what he thinks all these moves say about the evergreen “consumer vs. professional” question, to what the company’s new devices (namely tablets, personal computers, and TVs) tell us about the long arc of innovation.

Apple Event: Desktop-Tablet Convergence, Cord-Cutting, "Find Anything," & More

If the best way to know whether a medicine is effective is through a clinical trial, then where does (and doesn't) real-world data and real-world evidence come in? The topic is always top of mind in drug development, with additional focus as of 2016 thanks to the 21st Century Cures Act -- but is especially heated lately given recent concerns and claims around particular drugs in the context of the novel coronavirus pandemic.

So in this short-but-deep dive episode of 16 Minutes on the News, a16z general partner in bio Vijay Pande -- previously a professor of Chemistry, Structural Biology, and Computer Science at Stanford University (as well as founder of Folding@Home) -- breaks down the debate between RWE vs. RCT (real world evidence and randomized controlled trials), in conversation with Sonal Chokshi. Is it a tradeoff between speed of innovation and safety, or is it a false dichotomy altogether? Where do and don't statistics come in when it comes to policy? How has, and could, the role of the FDA (as well as payers reimbursing healthcare) evolve here? And where can technology help?

Drugs & Debates: Real World Data, Randomized Controlled Trials

Escucha y lee

Otros podcasts que te pueden gustar...